Sort
82,697 grants matching “vaccine development”
Project 1 - Immune profiling of natural dengue virus infections
$1,235,755Eva Harris · Icahn School Of Medicine At Mount Sinai · U19 · FY2017 · AI
Antigen Processing And Presentation In The Intestine
$1,235,645Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Host Immunity Against Bacteria
$1,235,174Sandip Datta · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
CNH/EID: The Vector Mosquito Aedes aegypti at the Margins: Sensitivity of a Coupled Natural and Human System to Climate Change
$1,235,153Andrew Monaghan · University Corporation For Atmospheric Res · · FY2010 · GEO
Improved Anthrax Vaccine Stability &use of Adjuvants
$1,235,070Pharmathene Uk Limited · UC1 · FY2005 · AI
The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) Study
$1,235,066Sarah Cobey · University Of Chicago · U01 · FY2023 · AI
CLINICAL EPIDEMIOLOGY &PATHOGENESIS OF ASYMPTOMATIC HSV
$1,234,634Fred Hutchinson Cancer Research Center · P01 · FY2001 · AI
Immunogen Design and Selection
$1,234,493Richard Thomas Wyatt · Scripps Research Institute, The · P01 · FY2017 · AI
Task A31: Small Animal Models for Testing Vaccines and Therapeutics
$1,234,323Craig Franklin · University Of Missouri-Columbia · N01 · FY2011 · AI
IP21-002 Enhanced Surveillance for New Vaccine Preventable Diseases
$1,234,285Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2024 · IP
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness
$1,234,285Geoffrey Alan Weinberg · University Of Rochester · U01 · FY2024 · IP
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,234,285Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2024 · IP
Production of Pedigreed SPF Rhesus Macaques
$1,234,230University Of California Davis · U42 · FY2005 · RR
Technology Component
$1,234,077John Barker Harley · Oklahoma Medical Research Foundation · U19 · FY2007 · AI
Env evolution in humans and RMs
$1,234,052George M Shaw · University Of Pennsylvania · P01 · FY2019 · AI
Miami HIV/AIDS Clinical Therapeutic and Vaccine Trial Unit
$1,233,860Margaret A Fischl · University Of Miami School Of Medicine · U01 · FY2011 · AI
National Resource for Automated Molecular Microscopy
$1,233,858Bridget Olivia Carragher · New York Structural Biology Center · P41 · FY2016 · GM
Cardiac Transplantation in Infancy
$1,233,621Jeffrey L Platt · Mayo Clinic Rochester · P01 · FY2006 · HL
Task X19: Development of Assays and Reagents for Zika Virus Vaccines
$1,233,564Randi Hornback · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2016 · AI
Structural Approaches to HIV-1 Immunogen Design and BNAb Analysis
$1,233,525Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2016 · AI
B Cell and Antibody Responses Following Live Attenuated Dengue Virus Vaccination
$1,233,328Aravinda M De Silva · University Of California Berkeley · P01 · FY2016 · AI
Mayo Clinic SPORE in Pancreatic Cancer
$1,233,307Gloria M. Petersen · Mayo Clinic Rochester · P50 · FY2013 · CA
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development
$1,233,253Edward T. Ryan · Massachusetts General Hospital · U01 · FY2008 · AI
Task C9: Production and distribution of Filarial Research Reagents
$1,233,189Andrew Moorhead · University Of Georgia · N01 · FY2021 · AI
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
$1,233,011Ann E. Jerse · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2018 · AI